Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Identification of potential therapeutic targets in prostate cancer through a cross-species approach.

Jurmeister S, Ramos-Montoya A, Sandi C, Pértega-Gomes N, Wadhwa K, Lamb AD, Dunning MJ, Attig J, Carroll JS, Fryer LG, Felisbino SL, Neal DE.

EMBO Mol Med. 2018 Mar;10(3). pii: e8274. doi: 10.15252/emmm.201708274.

2.

Corrigendum to "Integration of Copy Number and Transcriptomics Provides Risk Stratification in Prostate Cancer: A Discovery and Validation Cohort Study" [EBioMedicine 2 (9) (2015) 1133-1144].

Ross-Adams H, Lamb AD, Dunning MJ, Halim S, Lindberg J, Massie CM, Egevad LA, Russell R, Ramos-Montoya A, Vowler SL, Sharma NL, Kay J, Whitaker H, Clark J, Hurst R, Gnanapragasam VJ, Shah NC, Warren AY, Cooper CS, Lynch AG, Stark R, Mills IG, Grönberg H, Neal DE; CamCaP Study Group.

EBioMedicine. 2017 Mar;17:238. doi: 10.1016/j.ebiom.2017.03.010. Epub 2017 Mar 8. No abstract available.

3.

Asporin is a stromally expressed marker associated with prostate cancer progression.

Rochette A, Boufaied N, Scarlata E, Hamel L, Brimo F, Whitaker HC, Ramos-Montoya A, Neal DE, Dragomir A, Aprikian A, Chevalier S, Thomson AA.

Br J Cancer. 2017 Mar 14;116(6):775-784. doi: 10.1038/bjc.2017.15. Epub 2017 Feb 2.

4.

Loss of hSef promotes metastasis through upregulation of EMT in prostate cancer.

Hori S, Wadhwa K, Pisupati V, Zecchini V, Ramos-Montoya A, Warren AY, Neal DE, Gnanapragasam VJ.

Int J Cancer. 2017 Apr 15;140(8):1881-1887. doi: 10.1002/ijc.30604. Epub 2017 Jan 30.

5.

HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer.

Ross-Adams H, Ball S, Lawrenson K, Halim S, Russell R, Wells C, Strand SH, Ørntoft TF, Larson M, Armasu S, Massie CE, Asim M, Mortensen MM, Borre M, Woodfine K, Warren AY, Lamb AD, Kay J, Whitaker H, Ramos-Montoya A, Murrell A, Sørensen KD, Fridley BL, Goode EL, Gayther SA, Masters J, Neal DE, Mills IG.

Oncotarget. 2016 Nov 15;7(46):74734-74746. doi: 10.18632/oncotarget.12543.

6.

The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer.

Shaw GL, Whitaker H, Corcoran M, Dunning MJ, Luxton H, Kay J, Massie CE, Miller JL, Lamb AD, Ross-Adams H, Russell R, Nelson AW, Eldridge MD, Lynch AG, Ramos-Montoya A, Mills IG, Taylor AE, Arlt W, Shah N, Warren AY, Neal DE.

Eur Urol. 2016 Aug;70(2):214-8. doi: 10.1016/j.eururo.2015.10.042. Epub 2015 Nov 10.

7.

Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study.

Ross-Adams H, Lamb AD, Dunning MJ, Halim S, Lindberg J, Massie CM, Egevad LA, Russell R, Ramos-Montoya A, Vowler SL, Sharma NL, Kay J, Whitaker H, Clark J, Hurst R, Gnanapragasam VJ, Shah NC, Warren AY, Cooper CS, Lynch AG, Stark R, Mills IG, Grönberg H, Neal DE; CamCaP Study Group.

EBioMedicine. 2015 Jul 29;2(9):1133-44. doi: 10.1016/j.ebiom.2015.07.017. eCollection 2015 Sep. Erratum in: EBioMedicine. 2017 Mar;17 :238.

8.

A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy.

Pertega-Gomes N, Felisbino S, Massie CE, Vizcaino JR, Coelho R, Sandi C, Simoes-Sousa S, Jurmeister S, Ramos-Montoya A, Asim M, Tran M, Oliveira E, Lobo da Cunha A, Maximo V, Baltazar F, Neal DE, Fryer LG.

J Pathol. 2015 Aug;236(4):517-30. doi: 10.1002/path.4547.

9.

HES5 silencing is an early and recurrent change in prostate tumourigenesis.

Massie CE, Spiteri I, Ross-Adams H, Luxton H, Kay J, Whitaker HC, Dunning MJ, Lamb AD, Ramos-Montoya A, Brewer DS, Cooper CS, Eeles R; UK Prostate ICGC Group, Warren AY, Tavaré S, Neal DE, Lynch AG.

Endocr Relat Cancer. 2015 Apr;22(2):131-44. doi: 10.1530/ERC-14-0454. Epub 2015 Jan 5.

10.

Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer.

Bon H, Wadhwa K, Schreiner A, Osborne M, Carroll T, Ramos-Montoya A, Ross-Adams H, Visser M, Hoffmann R, Ahmed AA, Neal DE, Mills IG.

Mol Cancer Res. 2015 Apr;13(4):620-635. doi: 10.1158/1541-7786.MCR-13-0182-T. Epub 2014 Dec 29.

11.

Stat3 controls cell death during mammary gland involution by regulating uptake of milk fat globules and lysosomal membrane permeabilization.

Sargeant TJ, Lloyd-Lewis B, Resemann HK, Ramos-Montoya A, Skepper J, Watson CJ.

Nat Cell Biol. 2014 Nov;16(11):1057-1068. doi: 10.1038/ncb3043. Epub 2014 Oct 5.

12.

Transcriptomic analysis reveals inhibition of androgen receptor activity by AMPK in prostate cancer cells.

Jurmeister S, Ramos-Montoya A, Neal DE, Fryer LG.

Oncotarget. 2014 Jun 15;5(11):3785-99.

13.

Late Imaging with [1-(11)C]Acetate Improves Detection of Tumor Fatty Acid Synthesis with PET.

Lewis DY, Boren J, Shaw GL, Bielik R, Ramos-Montoya A, Larkin TJ, Martins CP, Neal DE, Soloviev D, Brindle KM.

J Nucl Med. 2014 Jul;55(7):1144-9. doi: 10.2967/jnumed.113.134437. Epub 2014 Apr 28.

14.

The ETS family member GABPα modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer.

Sharma NL, Massie CE, Butter F, Mann M, Bon H, Ramos-Montoya A, Menon S, Stark R, Lamb AD, Scott HE, Warren AY, Neal DE, Mills IG.

Nucleic Acids Res. 2014 Jun;42(10):6256-69. doi: 10.1093/nar/gku281. Epub 2014 Apr 21.

15.

HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network.

Ramos-Montoya A, Lamb AD, Russell R, Carroll T, Jurmeister S, Galeano-Dalmau N, Massie CE, Boren J, Bon H, Theodorou V, Vias M, Shaw GL, Sharma NL, Ross-Adams H, Scott HE, Vowler SL, Howat WJ, Warren AY, Wooster RF, Mills IG, Neal DE.

EMBO Mol Med. 2014 May;6(5):651-61. doi: 10.1002/emmm.201303581.

16.

N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 is overexpressed in cancer and promotes a pro-migratory and pro-metastatic phenotype.

Whitaker HC, Shiong LL, Kay JD, Grönberg H, Warren AY, Seipel A, Wiklund F, Thomas B, Wiklund P, Miller JL, Menon S, Ramos-Montoya A, Vowler SL, Massie C, Egevad L, Neal DE.

Oncogene. 2014 Nov 6;33(45):5274-87. doi: 10.1038/onc.2013.464. Epub 2013 Nov 18.

PMID:
24240687
17.

Downregulation of androgen receptor transcription by promoter g-quadruplex stabilization as a potential alternative treatment for castrate-resistant prostate cancer.

Mitchell T, Ramos-Montoya A, Di Antonio M, Murat P, Ohnmacht S, Micco M, Jurmeister S, Fryer L, Balasubramanian S, Neidle S, Neal DE.

Biochemistry. 2013 Feb 26;52(8):1429-36. doi: 10.1021/bi301349c. Epub 2013 Feb 11.

PMID:
23363071
18.

The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man.

Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, MacArthur S, Stark R, Warren AY, Mills IG, Neal DE.

Cancer Cell. 2013 Jan 14;23(1):35-47. doi: 10.1016/j.ccr.2012.11.010. Epub 2012 Dec 20.

19.

Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle.

Zanuy M, Ramos-Montoya A, Villacañas O, Canela N, Miranda A, Aguilar E, Agell N, Bachs O, Rubio-Martinez J, Pujol MD, Lee WN, Marin S, Cascante M.

Metabolomics. 2012 Jun 1;8(3):454-464. Epub 2011 Jul 8.

20.

Target metabolomics revealed complementary roles of hexose- and pentose-phosphates in the regulation of carbohydrate-dependent gene expression.

Diaz-Moralli S, Ramos-Montoya A, Marin S, Fernandez-Alvarez A, Casado M, Cascante M.

Am J Physiol Endocrinol Metab. 2012 Jul 15;303(2):E234-42. doi: 10.1152/ajpendo.00675.2011. Epub 2012 May 8.

21.

The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis.

Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, Warren A, Scott H, Madhu B, Sharma N, Bon H, Zecchini V, Smith DM, Denicola GM, Mathews N, Osborne M, Hadfield J, Macarthur S, Adryan B, Lyons SK, Brindle KM, Griffiths J, Gleave ME, Rennie PS, Neal DE, Mills IG.

EMBO J. 2011 May 20;30(13):2719-33. doi: 10.1038/emboj.2011.158.

22.

Cancer, chemistry, and the cell: molecules that interact with the neurotensin receptors.

Myers RM, Shearman JW, Kitching MO, Ramos-Montoya A, Neal DE, Ley SV.

ACS Chem Biol. 2009 Jul 17;4(7):503-25. doi: 10.1021/cb900038e. Review.

PMID:
19462983
23.

Terminal and progenitor lineage-survival oncogenes as cancer markers.

Vias M, Ramos-Montoya A, Mills IG.

Trends Mol Med. 2008 Nov;14(11):486-94. doi: 10.1016/j.molmed.2008.09.002. Epub 2008 Oct 15.

PMID:
18929510
24.

Pentose phosphate cycle oxidative and nonoxidative balance: A new vulnerable target for overcoming drug resistance in cancer.

Ramos-Montoya A, Lee WN, Bassilian S, Lim S, Trebukhina RV, Kazhyna MV, Ciudad CJ, Noé V, Centelles JJ, Cascante M.

Int J Cancer. 2006 Dec 15;119(12):2733-41.

25.

In situ localization of transketolase activity in epithelial cells of different rat tissues and subcellularly in liver parenchymal cells.

Boren J, Ramos-Montoya A, Bosch KS, Vreeling H, Jonker A, Centelles JJ, Cascante M, Frederiks WM.

J Histochem Cytochem. 2006 Feb;54(2):191-9. Epub 2005 Aug 22.

PMID:
16116031
26.

Rapid simulation and analysis of isotopomer distributions using constraints based on enzyme mechanisms: an example from HT29 cancer cells.

Selivanov VA, Meshalkina LE, Solovjeva ON, Kuchel PW, Ramos-Montoya A, Kochetov GA, Lee PW, Cascante M.

Bioinformatics. 2005 Sep 1;21(17):3558-64. Epub 2005 Jul 7.

PMID:
16002431
27.

An optimized algorithm for flux estimation from isotopomer distribution in glucose metabolites.

Selivanov VA, Puigjaner J, Sillero A, Centelles JJ, Ramos-Montoya A, Lee PW, Cascante M.

Bioinformatics. 2004 Dec 12;20(18):3387-97. Epub 2004 Jul 15.

PMID:
15256408

Supplemental Content

Loading ...
Support Center